Low dose evaluation of the antiandrogen flutamide following a Mode of Action approach

The dose–response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose–response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of...

Full description

Saved in:
Bibliographic Details
Published inToxicology and applied pharmacology Vol. 289; no. 3; pp. 515 - 524
Main Authors Sarrabay, A., Hilmi, C., Tinwell, H., Schorsch, F., Pallardy, M., Bars, R., Rouquié, D.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 15.12.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The dose–response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose–response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of the antiandrogen flutamide (FLU) on 7-week male Wistar rats. FLU was administered by oral gavage at doses of 0, 0.001, 0.01, 0.1, 1 and 10mg/kg/day for 28days. To evaluate the reproducibility, the study was performed 3 times. The molecular initiating event (MIE; AR antagonism), the key events (LH increase, Leydig cell proliferation and hyperplasia increases) and associated events involved in the mode of action (MOA) of FLU induced testicular toxicity were characterized to address the dose response concordance. Results showed no effects at low doses (<0.1mg/kg/day) for the different key events studied. The histopathological changes (Leydig cell hyperplasia) observed at 1 and 10mg/kg/day were associated with an increase in steroidogenesis gene expression in the testis from 1mg/kg/day, as well as an increase in testosterone blood level at 10mg/kg/day. Each key event dose–response was in good concordance with the MOA of FLU on the testis. From the available results, only monotonic dose–response curves were observed for the MIE, the key events, associated events and in effects observed in other sex related tissues. All the results, so far, show that the reference endocrine disruptor FLU induces threshold effects in a standard 28-day toxicity study on adult male rats. •Dose–response characterization of endocrine mediated toxicity is an on-going debate.•A wide range of dose levels of flutamide was evaluated on young adult male rats.•Flutamide induces threshold effects using on standard and molecular tools.
AbstractList The dose-response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose-response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of the antiandrogen flutamide (FLU) on 7-week male Wistar rats. FLU was administered by oral gavage at doses of 0, 0.001, 0.01, 0.1, 1 and 10mg/kg/day for 28days. To evaluate the reproducibility, the study was performed 3 times. The molecular initiating event (MIE; AR antagonism), the key events (LH increase, Leydig cell proliferation and hyperplasia increases) and associated events involved in the mode of action (MOA) of FLU induced testicular toxicity were characterized to address the dose response concordance. Results showed no effects at low doses (<0.1mg/kg/day) for the different key events studied. The histopathological changes (Leydig cell hyperplasia) observed at 1 and 10mg/kg/day were associated with an increase in steroidogenesis gene expression in the testis from 1mg/kg/day, as well as an increase in testosterone blood level at 10mg/kg/day. Each key event dose-response was in good concordance with the MOA of FLU on the testis. From the available results, only monotonic dose-response curves were observed for the MIE, the key events, associated events and in effects observed in other sex related tissues. All the results, so far, show that the reference endocrine disruptor FLU induces threshold effects in a standard 28-day toxicity study on adult male rats.
The dose–response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose–response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of the antiandrogen flutamide (FLU) on 7-week male Wistar rats. FLU was administered by oral gavage at doses of 0, 0.001, 0.01, 0.1, 1 and 10 mg/kg/day for 28 days. To evaluate the reproducibility, the study was performed 3 times. The molecular initiating event (MIE; AR antagonism), the key events (LH increase, Leydig cell proliferation and hyperplasia increases) and associated events involved in the mode of action (MOA) of FLU induced testicular toxicity were characterized to address the dose response concordance. Results showed no effects at low doses (< 0.1 mg/kg/day) for the different key events studied. The histopathological changes (Leydig cell hyperplasia) observed at 1 and 10 mg/kg/day were associated with an increase in steroidogenesis gene expression in the testis from 1 mg/kg/day, as well as an increase in testosterone blood level at 10 mg/kg/day. Each key event dose–response was in good concordance with the MOA of FLU on the testis. From the available results, only monotonic dose–response curves were observed for the MIE, the key events, associated events and in effects observed in other sex related tissues. All the results, so far, show that the reference endocrine disruptor FLU induces threshold effects in a standard 28-day toxicity study on adult male rats. - Highlights: • Dose–response characterization of endocrine mediated toxicity is an on-going debate. • A wide range of dose levels of flutamide was evaluated on young adult male rats. • Flutamide induces threshold effects using on standard and molecular tools.
The dose-response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose-response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of the antiandrogen flutamide (FLU) on 7-week male Wistar rats. FLU was administered by oral gavage at doses of 0, 0.001, 0.01, 0.1, 1 and 10mg/kg/day for 28 days. To evaluate the reproducibility, the study was performed 3 times. The molecular initiating event (MIE; AR antagonism), the key events (LH increase, Leydig cell proliferation and hyperplasia increases) and associated events involved in the mode of action (MOA) of FLU induced testicular toxicity were characterized to address the dose response concordance. Results showed no effects at low doses (<0.1mg/kg/day) for the different key events studied. The histopathological changes (Leydig cell hyperplasia) observed at 1 and 10mg/kg/day were associated with an increase in steroidogenesis gene expression in the testis from 1mg/kg/day, as well as an increase in testosterone blood level at 10mg/kg/day. Each key event dose-response was in good concordance with the MOA of FLU on the testis. From the available results, only monotonic dose-response curves were observed for the MIE, the key events, associated events and in effects observed in other sex related tissues. All the results, so far, show that the reference endocrine disruptor FLU induces threshold effects in a standard 28-day toxicity study on adult male rats.
The dose–response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose–response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of the antiandrogen flutamide (FLU) on 7-week male Wistar rats. FLU was administered by oral gavage at doses of 0, 0.001, 0.01, 0.1, 1 and 10mg/kg/day for 28days. To evaluate the reproducibility, the study was performed 3 times. The molecular initiating event (MIE; AR antagonism), the key events (LH increase, Leydig cell proliferation and hyperplasia increases) and associated events involved in the mode of action (MOA) of FLU induced testicular toxicity were characterized to address the dose response concordance. Results showed no effects at low doses (<0.1mg/kg/day) for the different key events studied. The histopathological changes (Leydig cell hyperplasia) observed at 1 and 10mg/kg/day were associated with an increase in steroidogenesis gene expression in the testis from 1mg/kg/day, as well as an increase in testosterone blood level at 10mg/kg/day. Each key event dose–response was in good concordance with the MOA of FLU on the testis. From the available results, only monotonic dose–response curves were observed for the MIE, the key events, associated events and in effects observed in other sex related tissues. All the results, so far, show that the reference endocrine disruptor FLU induces threshold effects in a standard 28-day toxicity study on adult male rats. •Dose–response characterization of endocrine mediated toxicity is an on-going debate.•A wide range of dose levels of flutamide was evaluated on young adult male rats.•Flutamide induces threshold effects using on standard and molecular tools.
Author Hilmi, C.
Tinwell, H.
Schorsch, F.
Rouquié, D.
Bars, R.
Pallardy, M.
Sarrabay, A.
Author_xml – sequence: 1
  givenname: A.
  surname: Sarrabay
  fullname: Sarrabay, A.
  organization: INSERM, Université Paris-Sud, Faculté de Pharmacie, Châtenay-Malabry, France
– sequence: 2
  givenname: C.
  surname: Hilmi
  fullname: Hilmi, C.
  organization: Bayer SAS, 16, rue Jean Marie Leclair, 69009 Lyon, France
– sequence: 3
  givenname: H.
  surname: Tinwell
  fullname: Tinwell, H.
  organization: Bayer SAS, 16, rue Jean Marie Leclair, 69009 Lyon, France
– sequence: 4
  givenname: F.
  surname: Schorsch
  fullname: Schorsch, F.
  organization: Bayer SAS, 16, rue Jean Marie Leclair, 69009 Lyon, France
– sequence: 5
  givenname: M.
  surname: Pallardy
  fullname: Pallardy, M.
  organization: INSERM, Université Paris-Sud, Faculté de Pharmacie, Châtenay-Malabry, France
– sequence: 6
  givenname: R.
  surname: Bars
  fullname: Bars, R.
  organization: Bayer SAS, 16, rue Jean Marie Leclair, 69009 Lyon, France
– sequence: 7
  givenname: D.
  surname: Rouquié
  fullname: Rouquié, D.
  email: david.rouquie@bayer.com
  organization: Bayer SAS, 16, rue Jean Marie Leclair, 69009 Lyon, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26485406$$D View this record in MEDLINE/PubMed
https://www.osti.gov/biblio/22687856$$D View this record in Osti.gov
BookMark eNp9kMFq3DAURUVJaSZpf6CLIuimG0-fJEu2oZsQ0qYwpZsEshOy_JTR4JGmlpzQv4_cSbPM6sHl3MvjnJGTEAMS8pHBmgFTX3frbMxhzYHJEqwBujdkxaBTFQghTsgKoGYVQHt3Ss5S2kEh6pq9I6dc1a2sQa3I7SY-0iEmpPhgxtlkHwONjuYtUhOyN2GY4j0G6sY5m70fkLo4jvHRh3tq6K9YgoJf2H9FczhM0djte_LWmTHhh-d7Tm6_X91cXleb3z9-Xl5sKluzJldO9IMC46yyKGUnGoeuh6YT0rFGOd4L23SDkwa5azsDAlXLTV9LK7jAdhDn5PNxN6bsdbI-o93aGALarDlXbdNKVagvR6o892fGlPXeJ4vjaALGOWnWSMYZk7Cg_IjaKaY0odOHye_N9Fcz0It0vdOLdL1IX7KitJQ-Pe_P_R6Hl8p_ywX4dgSwuHjwOC2vYrA4-Gn5dIj-tf0ndnqUwg
CitedBy_id crossref_primary_10_1080_03639045_2023_2182124
crossref_primary_10_1186_s12958_020_00582_3
crossref_primary_10_3390_ijms21124439
crossref_primary_10_1093_toxsci_kfx135
crossref_primary_10_1016_j_bmcl_2020_127507
crossref_primary_10_56766_ntms_1441182
crossref_primary_10_1134_S1990519X21040088
crossref_primary_10_1016_j_comtox_2019_100098
crossref_primary_10_1016_j_surfin_2023_103195
crossref_primary_10_1038_s41598_021_93292_8
Cites_doi 10.1016/j.chemosphere.2013.06.043
10.1016/j.taap.2014.01.017
10.1124/dmd.105.009159
10.1095/biolreprod.104.039321
10.1038/490462a
10.1002/1097-0142(19931215)72:12+<3816::AID-CNCR2820721711>3.0.CO;2-3
10.1007/s00204-010-0640-7
10.1093/toxsci/kfp056
10.1016/j.envpol.2013.07.046
10.1007/s002040050664
10.3109/10408444.2010.541225
10.1210/er.2008-0021
10.1016/B978-0-12-800095-3.00005-5
10.1210/er.2011-1050
10.1016/0002-9343(92)90741-S
10.1093/toxsci/kfm022
10.1289/ehp.0900887
10.1007/s002040100214
10.1124/dmd.105.008623
10.3109/10408444.2014.931925
10.1006/rtph.2001.1493
10.1093/toxsci/kfr099
ContentType Journal Article
Copyright 2015 Elsevier Inc.
Copyright © 2015 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2015 Elsevier Inc.
– notice: Copyright © 2015 Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7U7
C1K
OTOTI
DOI 10.1016/j.taap.2015.10.009
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Toxicology Abstracts
Environmental Sciences and Pollution Management
OSTI.GOV
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Toxicology Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList Toxicology Abstracts

MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 1096-0333
EndPage 524
ExternalDocumentID 22687856
10_1016_j_taap_2015_10_009
26485406
S0041008X15301125
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.~1
0R~
123
1B1
1RT
1~.
1~5
4.4
457
4G.
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKC
AAIKJ
AAKOC
AALRI
AAMNW
AAOAW
AAQFI
AATCM
AAXUO
ABFRF
ABFYP
ABJNI
ABLST
ABMAC
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHEUO
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AKIFW
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLECG
BLXMC
C45
CS3
DM4
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
IHE
J1W
KCYFY
KOM
LG5
M33
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
RIG
ROL
RPZ
SDF
SDG
SDP
SES
SPCBC
SSJ
SSP
SSZ
T5K
TEORI
TWZ
WH7
ZU3
~G-
AAXKI
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
.55
.GJ
.HR
29Q
3O-
53G
AAQXK
AAYXX
ABEFU
ABFNM
ABXDB
ADFGL
ADMUD
AFFNX
AFJKZ
AHHHB
ASPBG
AVWKF
AZFZN
CAG
CITATION
COF
FEDTE
FGOYB
G-2
HMT
HVGLF
HZ~
R2-
SEW
SPT
UHS
WUQ
X7M
XJT
XPP
Y6R
YCJ
ZGI
ZKB
ZMT
ZXP
~KM
7U7
C1K
AALMO
AAPBV
ABPIF
ABPTK
ABQIS
EFJIC
OTOTI
ID FETCH-LOGICAL-c417t-f3bd60afc6ce55937fefb07935f176f2b3c79df5ae2f89a03e682ab45c323e8d3
IEDL.DBID .~1
ISSN 0041-008X
IngestDate Thu May 18 22:32:34 EDT 2023
Fri Oct 25 07:39:09 EDT 2024
Thu Sep 26 19:22:21 EDT 2024
Sat Sep 28 07:57:33 EDT 2024
Fri Feb 23 02:29:39 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Low-dose
Flutamide
Leydig cell hyperplasia
Mode of action
Threshold
Language English
License Copyright © 2015 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c417t-f3bd60afc6ce55937fefb07935f176f2b3c79df5ae2f89a03e682ab45c323e8d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 26485406
PQID 1751211506
PQPubID 23462
PageCount 10
ParticipantIDs osti_scitechconnect_22687856
proquest_miscellaneous_1751211506
crossref_primary_10_1016_j_taap_2015_10_009
pubmed_primary_26485406
elsevier_sciencedirect_doi_10_1016_j_taap_2015_10_009
PublicationCentury 2000
PublicationDate 2015-12-15
PublicationDateYYYYMMDD 2015-12-15
PublicationDate_xml – month: 12
  year: 2015
  text: 2015-12-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Toxicology and applied pharmacology
PublicationTitleAlternate Toxicol Appl Pharmacol
PublicationYear 2015
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Myers, Zoeller, vom Saal (bb0110) 2009; 117
Carmichael, Bausen, Boobis, Cohen, Embry, Fruijtier-Pölloth, Greim, Lewis, Bette Meek, Mellor, Vickers, Doe (bb0035) 2011; 41
Labrie (bb0085) 1993; 72
Beausoleil, Ormsby, Gies, Hass, Heindel, Holmer, Nielsen, Munn, Schoenfelder (bb0025) 2013; 93
Sonich-Mullin, Fielder, Wiltse, Baetcke, Dempsey, Fenner-Crisp, Grant, Hartley, Knaap, Kroese, Mangelsdorf, Meek, Rice, Younes (bb0170) 2001; 34
Council (bb0050) 2014
Friry-Santini, Rouquié, Kennel, Tinwell, Benahmed, Bars (bb0065) 2007; 97
Vandenberg (bb0195) 2014
Schering (bb0145) 2000
Goda, Nagai, Akiyama, Nishikawa, Ikemoto, Aizawa, Nagata, Yamazoe (bb0070) 2006; 34
European Chemicals Agency (bb0055) 2014
Gomez, Dupont, Cusan, Tremblay, Suburu, Lemay, Labrie (bb0075) 1992; 92
Toyoda, Shibutani, Tamura, Koujitani, Uneyama, Hirose (bb0185) 2000; 74
Calabrese (bb0030) 2013; 182
Simon, S., Preston, Boobis, Cohen, Doerrer, Fenner-Crisp, McMullin, McQueen, Rowlands, Dose-response (bb0155) 2014; 8444
Odum (bb0125) 2013
National Toxicology Program, U.S. Environmental Protection Agency (bb0115) 2001
Rouquié, Friry-Santini, Schorsch, Tinwell, Bars (bb0135) 2009; 109
Shimamoto, Dewa, Kemmochi, Taniai, Hayashi, Imaoka, Shibutani, Mitsumori (bb0150) 2011; 85
Andrews, Freyberger, Hartmann, Eiben, Loof, Schmidt, Temerowski, Becka (bb0005) 2001; 75
Simoni, Weinbauer, Gromoll, Nieschlag (bb0160) 1999; 60
Leone, Nie, Brandon Parker, Sawant, Piechta, Kelley, Mark Kao, Jim Proctor, Verheyen, Johnson, Lord, McMillian (bb0095) 2014; 275
Hass, Christiansen, Axelstad, Sørensen, Boberg (bb0080) 2013
Sufrin, Coffey (bb0180) 1976; 13
Royal Society of Chemistry (bb0140) 2014
OECD (bb0130) 2013
Autrup, Barile, Blaauboer, Degen, Dekant, Dietrich, Domingo, Gori, Greim, Hengstler, Kacew, Marquardt, Pelkonen, Savolainen, Vermeulen (bb0010) 2015
Ludwig, Tinwell, Schorsch, Cavaillé, Pallardy, Rouquié, Bars (bb0100) 2011; 122
Vandenberg, Maffini, Sonnenschein, Rubin, Soto (bb0205) 2009; 30
Wetherill, Petre, Monk, Puga, Knudsen (bb0210) 2002; 1
Coe, Nelson, Ulrich, He, Dai, Cheng, Caguyong, Roberts, Slatter (bb0045) 2006; 34
U.S. Environmental Protection Agency (bb0190) 2013
Meachem, Stanton, Schlatt (bb0105) 2005; 72
Fagin (bb0060) 2012; 490
Vandenberg, Colborn, Hayes, Heindel, Jacobs, Lee, Shioda, Soto, vom Saal, Welshons, Zoeller, Myers (bb0200) 2012; 33
Toyoda (10.1016/j.taap.2015.10.009_bb0185) 2000; 74
National Toxicology Program, U.S. Environmental Protection Agency (10.1016/j.taap.2015.10.009_bb0115) 2001
Vandenberg (10.1016/j.taap.2015.10.009_bb0195) 2014
Vandenberg (10.1016/j.taap.2015.10.009_bb0200) 2012; 33
Carmichael (10.1016/j.taap.2015.10.009_bb0035) 2011; 41
Labrie (10.1016/j.taap.2015.10.009_bb0085) 1993; 72
Ludwig (10.1016/j.taap.2015.10.009_bb0100) 2011; 122
Schering (10.1016/j.taap.2015.10.009_bb0145) 2000
Vandenberg (10.1016/j.taap.2015.10.009_bb0205) 2009; 30
Gomez (10.1016/j.taap.2015.10.009_bb0075) 1992; 92
Sufrin (10.1016/j.taap.2015.10.009_bb0180) 1976; 13
Hass (10.1016/j.taap.2015.10.009_bb0080) 2013
Calabrese (10.1016/j.taap.2015.10.009_bb0030) 2013; 182
Rouquié (10.1016/j.taap.2015.10.009_bb0135) 2009; 109
Leone (10.1016/j.taap.2015.10.009_bb0095) 2014; 275
OECD (10.1016/j.taap.2015.10.009_bb0130) 2013
Council (10.1016/j.taap.2015.10.009_bb0050) 2014
U.S. Environmental Protection Agency (10.1016/j.taap.2015.10.009_bb0190) 2013
Simoni (10.1016/j.taap.2015.10.009_bb0160) 1999; 60
Goda (10.1016/j.taap.2015.10.009_bb0070) 2006; 34
Myers (10.1016/j.taap.2015.10.009_bb0110) 2009; 117
Odum (10.1016/j.taap.2015.10.009_bb0125) 2013
Sonich-Mullin (10.1016/j.taap.2015.10.009_bb0170) 2001; 34
Wetherill (10.1016/j.taap.2015.10.009_bb0210) 2002; 1
Fagin (10.1016/j.taap.2015.10.009_bb0060) 2012; 490
Simon (10.1016/j.taap.2015.10.009_bb0155) 2014; 8444
Beausoleil (10.1016/j.taap.2015.10.009_bb0025) 2013; 93
Coe (10.1016/j.taap.2015.10.009_bb0045) 2006; 34
Royal Society of Chemistry (10.1016/j.taap.2015.10.009_bb0140) 2014
Andrews (10.1016/j.taap.2015.10.009_bb0005) 2001; 75
Shimamoto (10.1016/j.taap.2015.10.009_bb0150) 2011; 85
Friry-Santini (10.1016/j.taap.2015.10.009_bb0065) 2007; 97
Meachem (10.1016/j.taap.2015.10.009_bb0105) 2005; 72
European Chemicals Agency (10.1016/j.taap.2015.10.009_bb0055) 2014
Autrup (10.1016/j.taap.2015.10.009_bb0010) 2015
References_xml – volume: 275
  start-page: 189
  year: 2014
  end-page: 197
  ident: bb0095
  article-title: Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants
  publication-title: Toxicol. Appl. Pharmacol.
  contributor:
    fullname: McMillian
– start-page: 45
  year: 2013
  ident: bb0130
  article-title: Guidance document on developing and assessing Adverse Outcome Pathways
  publication-title: Iomc/Oecd 184
  contributor:
    fullname: OECD
– volume: 97
  start-page: 81
  year: 2007
  end-page: 93
  ident: bb0065
  article-title: Correlation between protein accumulation profiles and conventional toxicological findings using a model antiandrogenic compound, flutamide
  publication-title: Toxicol. Sci.
  contributor:
    fullname: Bars
– volume: 13
  start-page: 429
  year: 1976
  end-page: 434
  ident: bb0180
  article-title: Flutamide. Mechanism of action of a new nonsteroidal antiandrogen
  publication-title: Investig. Urol.
  contributor:
    fullname: Coffey
– volume: 85
  start-page: 1159
  year: 2011
  end-page: 1166
  ident: bb0150
  article-title: Relationship between CYP1A induction by indole-3-carbinol or flutamide and liver tumor-promoting potential in rats
  publication-title: Arch. Toxicol.
  contributor:
    fullname: Mitsumori
– volume: 8444
  start-page: 17
  year: 2014
  end-page: 43
  ident: bb0155
  article-title: The use of mode of action information in risk assessment: quantitative key events/dose–response framework for modeling the dose–response for key events
  publication-title: Crit. Rev. Toxicol.
  contributor:
    fullname: Dose-response
– volume: 93
  start-page: 847
  year: 2013
  end-page: 856
  ident: bb0025
  article-title: Low dose effects and non-monotonic dose responses for endocrine active chemicals: science to practice workshop: workshop summary
  publication-title: Chemosphere
  contributor:
    fullname: Schoenfelder
– volume: 72
  start-page: 3816
  year: 1993
  end-page: 3827
  ident: bb0085
  article-title: Mechanism of action and pure antiandrogenic properties of flutamide
  publication-title: Cancer
  contributor:
    fullname: Labrie
– year: 2000
  ident: bb0145
  article-title: Eulexin (Flutamide) Capsules Prescribing Information
  contributor:
    fullname: Schering
– volume: 74
  start-page: 127
  year: 2000
  end-page: 132
  ident: bb0185
  article-title: Repeated dose (28
  publication-title: Arch. Toxicol.
  contributor:
    fullname: Hirose
– year: 2001
  ident: bb0115
  article-title: National Toxicology Program's Report of the National Toxicology Program's Report of the Endocrine Disruptors Low-Dose Peer Review
  contributor:
    fullname: National Toxicology Program, U.S. Environmental Protection Agency
– volume: 34
  start-page: 146
  year: 2001
  end-page: 152
  ident: bb0170
  article-title: IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis
  publication-title: Regul. Toxicol. Pharmacol.
  contributor:
    fullname: Younes
– start-page: 1
  year: 2015
  end-page: 5
  ident: bb0010
  article-title: Principles of pharmacology and toxicology also govern effects of chemicals on the endocrine system
  publication-title: Toxicol. Sci.
  contributor:
    fullname: Vermeulen
– volume: 490
  start-page: 5
  year: 2012
  end-page: 8
  ident: bb0060
  article-title: The learning curve
  publication-title: Nature
  contributor:
    fullname: Fagin
– volume: 182
  start-page: 452
  year: 2013
  end-page: 460
  ident: bb0030
  article-title: Biphasic dose responses in biology, toxicology and medicine: accounting for their generalizability and quantitative features
  publication-title: Environ. Pollut.
  contributor:
    fullname: Calabrese
– volume: 60
  start-page: 102
  year: 1999
  end-page: 106
  ident: bb0160
  article-title: Role of FSH in male gonadal function
  publication-title: Ann. Endocrinol.
  contributor:
    fullname: Nieschlag
– volume: 75
  start-page: 65
  year: 2001
  end-page: 73
  ident: bb0005
  article-title: Feasibility and potential gains of enhancing the subacute rat study protocol (OECD test guideline no. 407) by additional parameters selected to determine endocrine modulation. A pre-validation study to determine endocrine-mediated effects of the antiandro
  publication-title: Arch. Toxicol.
  contributor:
    fullname: Becka
– volume: 41
  start-page: 175
  year: 2011
  end-page: 186
  ident: bb0035
  article-title: Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview
  publication-title: Crit. Rev. Toxicol.
  contributor:
    fullname: Doe
– volume: 109
  start-page: 59
  year: 2009
  end-page: 65
  ident: bb0135
  article-title: Standard and molecular NOAELs for rat testicular toxicity induced by flutamide
  publication-title: Toxicol. Sci.
  contributor:
    fullname: Bars
– year: 2014
  ident: bb0140
  article-title: Royal Society of Chemistry Expert Panel on Endocrine Disrupter Low Dose Effects RSC London 4 th June 2014
  contributor:
    fullname: Royal Society of Chemistry
– volume: 34
  start-page: 828
  year: 2006
  end-page: 835
  ident: bb0070
  article-title: Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikem
  publication-title: Drug Metab. Dispos.
  contributor:
    fullname: Yamazoe
– volume: 117
  start-page: 1652
  year: 2009
  end-page: 1655
  ident: bb0110
  article-title: A clash of old and new scientific concepts in toxicity, with important implications for public health
  publication-title: Environ. Health Perspect.
  contributor:
    fullname: vom Saal
– volume: 30
  start-page: 75
  year: 2009
  end-page: 95
  ident: bb0205
  article-title: Bisphenol-a and the great divide: a review of controversies in the field of endocrine disruption
  publication-title: Endocr. Rev.
  contributor:
    fullname: Soto
– year: 2014
  ident: bb0195
  article-title: Low-dose effects of hormones and endocrine disruptors
  publication-title: Vitamins and Hormones
  contributor:
    fullname: Vandenberg
– year: 2013
  ident: bb0080
  article-title: Input for the REACH-review in 2013 on Endocrine Disrupters
  contributor:
    fullname: Boberg
– year: 2014
  ident: bb0055
  article-title: Mode of Action and Human Relevance Framework in the Context of Classification and Labelling (CLH) and Regulatory Assessment of Biocides and Pesticides
  contributor:
    fullname: European Chemicals Agency
– volume: 92
  start-page: 465
  year: 1992
  end-page: 470
  ident: bb0075
  article-title: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients
  publication-title: Am. J. Med.
  contributor:
    fullname: Labrie
– volume: 72
  start-page: 1187
  year: 2005
  end-page: 1193
  ident: bb0105
  article-title: Follicle-stimulating hormone regulates both Sertoli cell and spermatogonial populations in the adult photoinhibited Djungarian hamster testis
  publication-title: Biol. Reprod.
  contributor:
    fullname: Schlatt
– volume: 34
  start-page: 1266
  year: 2006
  end-page: 1275
  ident: bb0045
  article-title: Profiling the hepatic effects of flutamide in rats: a microarray comparison with classical aryl hydrocarbon receptor ligands and atypical CYP1A inducers
  publication-title: Drug Metab. Dispos.
  contributor:
    fullname: Slatter
– year: 2014
  ident: bb0050
  article-title: Review of the environmental protection agency's state-of-the-science evaluation of nonmonotonic dose–response relationships as they apply to endocrine disrupters on earth
  contributor:
    fullname: Council
– year: 2013
  ident: bb0125
  article-title: Low Dose Endocrine Dirsrupter Effects: Review of Substances for Further Study. Regulatory Science Associates, UK
  contributor:
    fullname: Odum
– volume: 1
  start-page: 515
  year: 2002
  end-page: 524
  ident: bb0210
  article-title: The xenoestrogen bisphenol a induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells
  publication-title: Mol. Cancer Ther.
  contributor:
    fullname: Knudsen
– year: 2013
  ident: bb0190
  article-title: State of the Science Evaluation: Nonmonotonic Dose Responses as They Apply to Estrogen, Androgen, and Thyroid Pathways and EPA Testing and Assessment Procedures
  contributor:
    fullname: U.S. Environmental Protection Agency
– volume: 122
  start-page: 52
  year: 2011
  end-page: 63
  ident: bb0100
  article-title: A molecular and phenotypic integrative approach to identify a no-effect dose level for antiandrogen-induced testicular toxicity
  publication-title: Toxicol. Sci.
  contributor:
    fullname: Bars
– volume: 33
  start-page: 378
  year: 2012
  end-page: 455
  ident: bb0200
  article-title: Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses
  publication-title: Endocr. Rev.
  contributor:
    fullname: Myers
– volume: 1
  start-page: 515
  year: 2002
  ident: 10.1016/j.taap.2015.10.009_bb0210
  article-title: The xenoestrogen bisphenol a induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells
  publication-title: Mol. Cancer Ther.
  contributor:
    fullname: Wetherill
– volume: 93
  start-page: 847
  year: 2013
  ident: 10.1016/j.taap.2015.10.009_bb0025
  article-title: Low dose effects and non-monotonic dose responses for endocrine active chemicals: science to practice workshop: workshop summary
  publication-title: Chemosphere
  doi: 10.1016/j.chemosphere.2013.06.043
  contributor:
    fullname: Beausoleil
– volume: 275
  start-page: 189
  year: 2014
  ident: 10.1016/j.taap.2015.10.009_bb0095
  article-title: Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants
  publication-title: Toxicol. Appl. Pharmacol.
  doi: 10.1016/j.taap.2014.01.017
  contributor:
    fullname: Leone
– volume: 34
  start-page: 1266
  year: 2006
  ident: 10.1016/j.taap.2015.10.009_bb0045
  article-title: Profiling the hepatic effects of flutamide in rats: a microarray comparison with classical aryl hydrocarbon receptor ligands and atypical CYP1A inducers
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.105.009159
  contributor:
    fullname: Coe
– volume: 72
  start-page: 1187
  year: 2005
  ident: 10.1016/j.taap.2015.10.009_bb0105
  article-title: Follicle-stimulating hormone regulates both Sertoli cell and spermatogonial populations in the adult photoinhibited Djungarian hamster testis
  publication-title: Biol. Reprod.
  doi: 10.1095/biolreprod.104.039321
  contributor:
    fullname: Meachem
– volume: 490
  start-page: 5
  year: 2012
  ident: 10.1016/j.taap.2015.10.009_bb0060
  article-title: The learning curve
  publication-title: Nature
  doi: 10.1038/490462a
  contributor:
    fullname: Fagin
– volume: 72
  start-page: 3816
  year: 1993
  ident: 10.1016/j.taap.2015.10.009_bb0085
  article-title: Mechanism of action and pure antiandrogenic properties of flutamide
  publication-title: Cancer
  doi: 10.1002/1097-0142(19931215)72:12+<3816::AID-CNCR2820721711>3.0.CO;2-3
  contributor:
    fullname: Labrie
– volume: 85
  start-page: 1159
  year: 2011
  ident: 10.1016/j.taap.2015.10.009_bb0150
  article-title: Relationship between CYP1A induction by indole-3-carbinol or flutamide and liver tumor-promoting potential in rats
  publication-title: Arch. Toxicol.
  doi: 10.1007/s00204-010-0640-7
  contributor:
    fullname: Shimamoto
– volume: 109
  start-page: 59
  year: 2009
  ident: 10.1016/j.taap.2015.10.009_bb0135
  article-title: Standard and molecular NOAELs for rat testicular toxicity induced by flutamide
  publication-title: Toxicol. Sci.
  doi: 10.1093/toxsci/kfp056
  contributor:
    fullname: Rouquié
– volume: 182
  start-page: 452
  year: 2013
  ident: 10.1016/j.taap.2015.10.009_bb0030
  article-title: Biphasic dose responses in biology, toxicology and medicine: accounting for their generalizability and quantitative features
  publication-title: Environ. Pollut.
  doi: 10.1016/j.envpol.2013.07.046
  contributor:
    fullname: Calabrese
– volume: 74
  start-page: 127
  year: 2000
  ident: 10.1016/j.taap.2015.10.009_bb0185
  article-title: Repeated dose (28days) oral toxicity study of flutamide in rats, based on the draft protocol for the “Enhanced OECD Test Guideline 407” for screening for endocrine-disrupting chemicals
  publication-title: Arch. Toxicol.
  doi: 10.1007/s002040050664
  contributor:
    fullname: Toyoda
– volume: 13
  start-page: 429
  year: 1976
  ident: 10.1016/j.taap.2015.10.009_bb0180
  article-title: Flutamide. Mechanism of action of a new nonsteroidal antiandrogen
  publication-title: Investig. Urol.
  contributor:
    fullname: Sufrin
– volume: 41
  start-page: 175
  year: 2011
  ident: 10.1016/j.taap.2015.10.009_bb0035
  article-title: Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview
  publication-title: Crit. Rev. Toxicol.
  doi: 10.3109/10408444.2010.541225
  contributor:
    fullname: Carmichael
– start-page: 45
  year: 2013
  ident: 10.1016/j.taap.2015.10.009_bb0130
  article-title: Guidance document on developing and assessing Adverse Outcome Pathways
  contributor:
    fullname: OECD
– year: 2014
  ident: 10.1016/j.taap.2015.10.009_bb0055
  contributor:
    fullname: European Chemicals Agency
– volume: 30
  start-page: 75
  year: 2009
  ident: 10.1016/j.taap.2015.10.009_bb0205
  article-title: Bisphenol-a and the great divide: a review of controversies in the field of endocrine disruption
  publication-title: Endocr. Rev.
  doi: 10.1210/er.2008-0021
  contributor:
    fullname: Vandenberg
– year: 2000
  ident: 10.1016/j.taap.2015.10.009_bb0145
  contributor:
    fullname: Schering
– year: 2014
  ident: 10.1016/j.taap.2015.10.009_bb0195
  article-title: Low-dose effects of hormones and endocrine disruptors
  doi: 10.1016/B978-0-12-800095-3.00005-5
  contributor:
    fullname: Vandenberg
– volume: 33
  start-page: 378
  year: 2012
  ident: 10.1016/j.taap.2015.10.009_bb0200
  article-title: Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses
  publication-title: Endocr. Rev.
  doi: 10.1210/er.2011-1050
  contributor:
    fullname: Vandenberg
– year: 2001
  ident: 10.1016/j.taap.2015.10.009_bb0115
  contributor:
    fullname: National Toxicology Program, U.S. Environmental Protection Agency
– year: 2013
  ident: 10.1016/j.taap.2015.10.009_bb0125
  contributor:
    fullname: Odum
– volume: 92
  start-page: 465
  year: 1992
  ident: 10.1016/j.taap.2015.10.009_bb0075
  article-title: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients
  publication-title: Am. J. Med.
  doi: 10.1016/0002-9343(92)90741-S
  contributor:
    fullname: Gomez
– year: 2013
  ident: 10.1016/j.taap.2015.10.009_bb0190
  contributor:
    fullname: U.S. Environmental Protection Agency
– year: 2014
  ident: 10.1016/j.taap.2015.10.009_bb0050
  contributor:
    fullname: Council
– volume: 60
  start-page: 102
  year: 1999
  ident: 10.1016/j.taap.2015.10.009_bb0160
  article-title: Role of FSH in male gonadal function
  publication-title: Ann. Endocrinol.
  contributor:
    fullname: Simoni
– volume: 97
  start-page: 81
  year: 2007
  ident: 10.1016/j.taap.2015.10.009_bb0065
  article-title: Correlation between protein accumulation profiles and conventional toxicological findings using a model antiandrogenic compound, flutamide
  publication-title: Toxicol. Sci.
  doi: 10.1093/toxsci/kfm022
  contributor:
    fullname: Friry-Santini
– volume: 117
  start-page: 1652
  year: 2009
  ident: 10.1016/j.taap.2015.10.009_bb0110
  article-title: A clash of old and new scientific concepts in toxicity, with important implications for public health
  publication-title: Environ. Health Perspect.
  doi: 10.1289/ehp.0900887
  contributor:
    fullname: Myers
– year: 2013
  ident: 10.1016/j.taap.2015.10.009_bb0080
  contributor:
    fullname: Hass
– volume: 75
  start-page: 65
  year: 2001
  ident: 10.1016/j.taap.2015.10.009_bb0005
  article-title: Feasibility and potential gains of enhancing the subacute rat study protocol (OECD test guideline no. 407) by additional parameters selected to determine endocrine modulation. A pre-validation study to determine endocrine-mediated effects of the antiandro
  publication-title: Arch. Toxicol.
  doi: 10.1007/s002040100214
  contributor:
    fullname: Andrews
– volume: 34
  start-page: 828
  year: 2006
  ident: 10.1016/j.taap.2015.10.009_bb0070
  article-title: Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikem
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.105.008623
  contributor:
    fullname: Goda
– volume: 8444
  start-page: 17
  year: 2014
  ident: 10.1016/j.taap.2015.10.009_bb0155
  article-title: The use of mode of action information in risk assessment: quantitative key events/dose–response framework for modeling the dose–response for key events
  publication-title: Crit. Rev. Toxicol.
  doi: 10.3109/10408444.2014.931925
  contributor:
    fullname: Simon
– year: 2014
  ident: 10.1016/j.taap.2015.10.009_bb0140
  contributor:
    fullname: Royal Society of Chemistry
– volume: 34
  start-page: 146
  year: 2001
  ident: 10.1016/j.taap.2015.10.009_bb0170
  article-title: IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis
  publication-title: Regul. Toxicol. Pharmacol.
  doi: 10.1006/rtph.2001.1493
  contributor:
    fullname: Sonich-Mullin
– volume: 122
  start-page: 52
  year: 2011
  ident: 10.1016/j.taap.2015.10.009_bb0100
  article-title: A molecular and phenotypic integrative approach to identify a no-effect dose level for antiandrogen-induced testicular toxicity
  publication-title: Toxicol. Sci.
  doi: 10.1093/toxsci/kfr099
  contributor:
    fullname: Ludwig
– start-page: 1
  year: 2015
  ident: 10.1016/j.taap.2015.10.009_bb0010
  article-title: Principles of pharmacology and toxicology also govern effects of chemicals on the endocrine system
  publication-title: Toxicol. Sci.
  contributor:
    fullname: Autrup
SSID ssj0009441
Score 2.2642114
Snippet The dose–response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose–response...
The dose-response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose-response...
SourceID osti
proquest
crossref
pubmed
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 515
SubjectTerms 60 APPLIED LIFE SCIENCES
Androgen Antagonists - pharmacology
ANIMAL TISSUES
Animals
ANTIANDROGENS
BLOOD
CELL PROLIFERATION
Dose-Response Relationship, Drug
DOSES
EVALUATION
Flutamide
Flutamide - pharmacology
Gene Expression - drug effects
Leydig cell hyperplasia
Leydig Cells - drug effects
Low-dose
Male
Mode of action
RATS
Rats, Wistar
Reproducibility of Results
TESTES
Testicular Diseases - blood
Testicular Diseases - genetics
TESTOSTERONE
Testosterone - blood
Threshold
TOXICITY
Title Low dose evaluation of the antiandrogen flutamide following a Mode of Action approach
URI https://dx.doi.org/10.1016/j.taap.2015.10.009
https://www.ncbi.nlm.nih.gov/pubmed/26485406
https://search.proquest.com/docview/1751211506
https://www.osti.gov/biblio/22687856
Volume 289
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT-MwEB2hckFarRbYjy4sMtKKyzaQxB9JjhUCFditemil3iInGUtF2gbRIsRlfzszcbIVBzhwjGVLlud5Zuy8eQb4GRVxKVEWAcVexaLaNkixSoIYUysxzOKiuRr4Mzajmbqe6_kWnHe1MEyrbH2_9-mNt25bztrVPLtbLLjGV7EyzZz2LIE05kJzReGPMH36b0PzyJTyr-YpOjZT77ZwxnO81tayZmWkTxuGV_ZacOrVtN9ez0GbWHT5CT62SaQY-nnuwhYu9-Bk4lWonwZiuimqWg3EiZhs9Kmf9uCDv6oTvgJpH2a_60dR1SsUG-lvUTtBqaGgdSf8VPc14Uw4Qqn9u6hQOEJP_UhRT1jBr6lx92FTISE6kfLPMLu8mJ6Pgva1haBUUbIOnCwqE1pXmhLpmCETh65g-TztosS4uJBlklVOW4xdmtlQokljWyhdylhiWskv0FvWS_wGAsPSRDaxtMFRKdY0k44ipeHznZOJ7sOvbpnzOy-qkXdss9ucjZKzUbiNjNIH3VkifwGNnLz-m-MO2Ww8hvVwSyYO0SDKN9Mk1aYPx505c9pS_J_ELrF-WOWUUbHwnQ6pz1dv5__TZEIgJbnm-zsndQA7_MWEmEgfQm99_4A_KK1ZF0cNbo9ge3h1Mxo_A-yQ9SE
link.rule.ids 230,315,783,787,888,4509,24128,27936,27937,45597,45691
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB6V9AASQlCgBFpYJNQLNbW9D9vHqKJKaRr1kEi5rdb2rBSkxlWTquq_Z8ZrE3Eoh17XO9Jq5_XteuZbgG9JmVYSZRlR7lVMqu2iHOssSjF3EuMiLdurgcupGc_Vr4Ve7MBp3wvDZZVd7A8xvY3W3chJt5snN8sl9_gqZqZZkM-Skab6GewSGijIO3dH5xfj6ZZ7V6nwcJ6ikzMJdL0zocxr4xzTVib6R1vkVTyWnwYNudzjMLRNR2ev4VWHI8UoLPUN7OBqD46uAhH1w7GYbfuq1sfiSFxtKaof9uBluK0ToQnpLcwnzb2omzWKLfu3aLwgdCho68mE6tuGTE14MlR3vaxReDKg5p4Sn3CCH1Tj6aO2SUL0POXvYH72c3Y6jroHF6JKJdkm8rKsTex8ZSqkk4bMPPqSGfS0TzLj01JWWVF77TD1eeFiiSZPXal0JVOJeS3fw2DVrPADCIwrk7jMkY-jUkxrJj0lS8NHPC8zPYTv_Tbbm8CrYfuCs9-WlWJZKTxGShmC7jVh_7EOS4H_v3IHrDaWYUrcimuHSIggZ57l2gzha69OS17Fv0rcCpu7tSVQxdx3OqY5-0HPf5fJNYGEc83HJy7qCzwfzy4ndnI-vfgEL_gL18ck-gAGm9s7PCSUsyk_d1b8B19S99U
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low+dose+evaluation+of+the+antiandrogen+flutamide+following+a+Mode+of+Action+approach&rft.jtitle=Toxicology+and+applied+pharmacology&rft.au=Sarrabay%2C+A.&rft.au=Hilmi%2C+C.&rft.au=Tinwell%2C+H.&rft.au=Schorsch%2C+F.&rft.date=2015-12-15&rft.pub=Elsevier+Inc&rft.issn=0041-008X&rft.eissn=1096-0333&rft.volume=289&rft.issue=3&rft.spage=515&rft.epage=524&rft_id=info:doi/10.1016%2Fj.taap.2015.10.009&rft.externalDocID=S0041008X15301125
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-008X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-008X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-008X&client=summon